Biotech Values

[vinmantoo]

Data from the Phase 1 study demonstrated favorable safety, tolerability, and PK supportive of once-daily dosing, with good exposure multiples, thereby supporting further clinical advancement of EDP-323. "With the significant unmet need for effective antivirals to treat patients with RSV, we are pleased to report positive Phase 1 results for EDP-323. These data demonstrate that EDP-323 was generally safe and well-tolerated up to 800 mg, with a PK profile supportive of once-daily dosing and strong exposure multiples across both RSV A and B strains" said Scott T. Rottinghaus, M.D., Senior Vice President and Chief Medical Officer of Enanta Pharmaceuticals.

Nice to see that a second RSV inhibitor from ENTA will be moving forward in trials.